Table 3.

Key Ongoing Phase 2 and 3 Clinical Trials with Ipilimumab

Indication	Phase/identifier	Design and interventions	Primary endpoint	Status
Treatment-naïve, advanced melanoma	Phase 3; CA184-024	Randomized; ipilimumab (10 mg/kg Q3W × 4, then Q12W)/DTIC versus DTIC	Improvement in OS	Active, not recruiting
High risk, stage III melanoma	Phase 3; CA184-029, EORTC 18071	Randomized; ipilimumab (10 mg/kg Q3W × 4) versus placebo	Improvement in recurrence-free survival	Recruiting
Pretreated CRPC	Phase 3; CA184-043	Randomized, ipilimumab (10 mg/kg Q3W × 4) versus placebo following radiotherapy	Improvement in OS	Recruiting
Treatment-naïve CRPC (minimally symptomatic)	Phase 3; CA184-095	Randomized; ipilimumab (10 mg/kg Q3W × 4, then Q12W) versus placebo	Improvement in OS	Recruiting
Treatment-naïve, advanced melanoma with brain metastases	Phase 2; NA	Non randomized; ipilimumab (10 mg/kg Q3W × 4, then Q12W) plus temozolomide	6-month PFS	Recruiting